Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed CF diagnosis with 2 clinical features~2. Documented history of EPI~3. Enteral formula use minimum of 4x/week~4. Written informed consent or assent, as applicable~Exclusion Criteria:~1. Uncontrolled diabetes mellitus~2. Signs and symptoms of liver cirrhosis or portal hypertension~3. Lung/liver transplant~4. Active cancer currently receiving cancer treatment~5. Crohn's or celiac disease, infectious gastroenteritis, sprue, lactose intolerant, inflammatory bowel disease~6. DIOS or fibrosing colonopathy

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- RELiZORB (Type: EXPERIMENTAL): Treatment (RELiZORB)
- Control (Type: PLACEBO_COMPARATOR): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).